Authors of a major influenza vaccine study have responded to methodological questions about their research. They defended their decision to conduct an individual-level pooled analysis of harmonized clinical trials. The team argues this approach represents the most statistically efficient way to analyze the collective data.
Their response addresses concerns about the FLUNITY-HD1 trial's design. The study examined higher doses of influenza vaccine, though the specific benefits remain unclear from the correspondence. The authors maintain their methodology was appropriate given the trial structures.
The researchers emphasize that two trials—DANFLU-22 and GALFLU3—were prospectively harmonized using identical protocols. This included shared endpoint hierarchies and variable definitions based on ICD-10 coding standards. Such harmonization made pooled analysis a suitable approach from the outset.
The correspondence suggests the FLUNITY-HD1 trial functions more like a single pragmatic trial across multiple sites than a conventional meta-analysis. This perspective supports their analytical choices. The debate highlights ongoing methodological discussions in vaccine efficacy research.
Scientific correspondence typically involves brief exchanges rather than comprehensive data presentations. Readers should consult the original research articles for complete trial results and detailed efficacy findings.